President and Chief Executive Officer

Rick Hancock has been involved in the biotechnology industry for the past twenty-seven years, serving previously as Althea’s Executive VP, Europe and prior to that as Althea’s COO. Mr. Hancock has been a leading figure in the area of gene-based therapeutics and DNA vaccine development. He also directed the design, construction, and regulatory assessment efforts for each of Althea’s current cGMP manufacturing facilities where he interacted with consultants, QP’s and government inspectors. Mr. Hancock has held process development and cGMP manufacturing positions at Hybritech/Eli Lilly, Genetics Institute (currently Pfizer Andover, MA facility) and previously as Senior Director of Operations at The Immune Response Corporation. He has extensive experience in the production of monoclonal antibodies, recombinant proteins, vaccine and gene therapy product development, and coordinated the establishment of Althea’s Fill/Finish operations. Additional areas of expertise include regulatory compliance in multi-product facilities, design and implementation of aseptic process validation, and complex formulation processing. Mr. Hancock began his career as a clinical microbiologist at Scripps Clinic and Research Foundation and holds a BA in microbiology from Miami University.

Sr. Vice President and Chief Financial Officer

Martha Demski has over 30 years of experience in the fields of finance and biotechnology. Most recently, Ms. Demski served as the Interim Chief Operating Officer and Chief Financial Officer of the Sidney Kimmel Cancer Center (SKCC). She previously served for over 15 years as Vice President and Chief Financial Officer of Vical Incorporated where she was responsible for multiple private and public financings including an IPO. Ms. Demski also spent over 12 years in banking with Bank of America, most recently as Senior Vice President in their U.S. Trust Division. It was at Bank of America that she first became involved in the biotech industry in 1978 when she funded the first equipment leases for Hybritech Inc. and a multitude of other biotech companies that followed. Her Board activities include the Board of Chimerix Inc. where she currently serves as Chair of the Audit committee. At SKCC she previously served on the Board of Trustees as Chair of the Audit Committee and prior to that, Chair of the Governance and Nominating Committee. Additionally, Ms. Demski previously served on the Finance and Audit Committees of the San Diego Foundation. She holds an M.B.A with concentrations in finance and accounting from The University of Chicago Booth School of Business, and a B.A. from Michigan State University.

Sr. Vice President of Operations

Mr. Duffy serves as a Corporate VP and has line management responsibility for all contract manufacturing divisions including the Biologics Manufacturing group and the Fill & Finish operations. Mr. Duffy has been with the company since the year 2000, and has partnered with more than 100 Althea customers to meet their development and manufacturing goals. Mr. Duffy has broad experience in all phases of biologics manufacturing with extensive experience in the manufacturing of recombinant protein therapeutics, vaccines, and combination products. Mr. Duffy has over 26 years of experience managing biopharmaceutical and sterile manufacturing operations. Prior to joining Althea he held management positions in Product Development and Manufacturing at The Immune Response Corporation where he managed development and manufacturing activities associated with the company’s HIV therapeutic vaccine, and cancer vaccine products.

Sr. Vice President of Quality and Regulatory

Mr. Brandreth brings over twenty years of experience in the regulatory and quality assurance fields in the biotechnology and pharmaceutical industries. He has managed numerous agency inspections and CMC submissions, and led the Process Validation Programs for five CBER/EMEA product launches, including Aldurazyme® , Naglazyme®, Zevalin®, and CBER’s first approved monoclonal antibody for cancer, Rituxan®. Prior to joining Althea Technologies he was Vice President of Quality at Favrille, Inc., specializing in personalized immunoglobulin therapies. Previous to Favrille, Mr. Brandreth was Senior Director of QA at BioMarin Pharmaceuticals, Inc. where he supported a variety of clinical drugs and the successful commercial launches of two CBER/EMEA products. He held management positions in Quality and Regulatory Affairs at IDEC Pharmaceuticals from 1992-1999. In the PDA Mr. Brandreth is currently the Chairman of the Biotech Advisory Board, an author of PDA TR 42, Process Validation of Protein Manufacturing, and was the Co-Chair of PDA TR 14, Validation of Chromatography Based Systems. He also serves on the BIOCOM FDA Advisory Board, the Interphex Advisory Board, and was a Director for 10 years, President of ISPE, San Diego Chapter. He holds a BS in Biology, UCSD, and a Masters in Business Administration

Vice President of Sales & Marketing

Jack Wright brings over fifteen years of experience in corporate sales and business development in the pharmaceutical industry. Jack joins Althea after serving as Vice President of Business Development for Oral Technologies at Catalent Pharma Solutions. Prior to his tenure at Catalent/Cardinal Health, Mr. Wright was with Rhodia Inc, Mutual Pharmaceutical and Bio-Pharm Pharmaceutical Services. He holds an M.B.A. with a concentration in finance from Drexel University, and a B.S. in Pharmacy from Rutgers College of Pharmacy.